Sponsor of the Day:
Jerkmate
https://www.rutgers.edu/news/long-acting-hiv-shots-appeal-many-uptake-remains-low
Long-Acting HIV Shots Appeal to Many but Uptake Remains Low | Rutgers University
Apr 23, 2026 - A Rutgers Health-led survey finds most people in HIV care would choose injections over daily pills, yet few are on the regimen.
long acting hivuptake remains lowrutgers universityshotsappeal
https://sph.rutgers.edu/news/long-acting-hiv-shots-appeal-many-uptake-remains-low
Long-Acting HIV Shots Appeal to Many but Uptake Remains Low | Rutgers School of Public Health
long acting hivuptake remains lowrutgers schoolpublic healthshots
https://www.standardmedia.co.ke/health/health-science/article/2001544713/long-acting-hiv-prevention-jab-records-no-major-health-concerns
Long-acting HIV prevention jab records no major health concerns - The Standard Health
Apr 7, 2026 - Kenya’s rollout of the HIV prevention drug Lenacapavir has recorded no major side effects, with experts reporting only mild, temporary pain at injection sites.
long acting hivmajor healthpreventionjabrecords